Preventive Effects of an EPA Preparation on Restenosis after Carotid Artery Stenting

Objective: The purpose of this study was to investigate the preventive effects of an eicosapentaenoic acid (EPA) medication on restenosis after carotid artery stenting (CAS).Methods: Of 134 patients (144 episodes) who underwent CAS in our hospital or affiliated institutions between November 2005 and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neuroendovascular Therapy 2018, Vol.12(11), pp.527-531
Main Authors: Ohashi, Tomoo, Arai, Yusuke, Kato, Daichi, Aoyagi, Shigeru, Okada, Hirofumi, Yokoyama, Tomoya, Ichikawa, Megumi, Nagai, Kenta, Namatame, Hiroaki, Saida, Akihiko, Hashimoto, Takao, Kono, Michihiro
Format: Article
Language:English
Subjects:
carotid artery stenting
eicosapentaenoic acid
restenosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The purpose of this study was to investigate the preventive effects of an eicosapentaenoic acid (EPA) medication on restenosis after carotid artery stenting (CAS).Methods: Of 134 patients (144 episodes) who underwent CAS in our hospital or affiliated institutions between November 2005 and September 2017, the subjects were 123 who could be followed-up for ≥30 days after procedure by carotid ultrasonography with a mean age of 73.3 years (range: 55–90 years). Males accounted for 106 (86.2%) of the patients, 61 lesions (49.6%) were symptomatic. We retrospectively compared the incidence of restenosis between the two groups: EPA-treated group (n = 43) and non-EPA-treated group (n = 80). In addition, the serum levels of fatty acid compositions had been analyzed in 97 of the 123 patients, and the relationship of the EPA/arachidonic acid (AA) ratio with perioperative ischemic complications or restenosis was examined.Results: There was no restenosis in any of the 43 EPA-treated patients, whereas it occurred in 8 (10%) of the 80 patients in the non-EPA-treated group, and the incidence of restenosis in EPA-treated group was significantly lower (p = 0.043) than that of non-EPA-treated group. In addition, the incidences of restenosis and perioperative ischemic complications were slightly higher in patients with a low EPA/AA ratio.Conclusion: Although restenosis was more frequent in patients with a low EPA/AA ratio, the administration of an EPA medication may prevent restenosis in all patients who underwent CAS.
ISSN:1882-4072
2186-2494
DOI:10.5797/jnet.oa.2018-0032